FRAMINGHAM (03/22/2004) - Chemogenomic pioneer Iconix Pharmaceuticals Inc. recently got a big boost from major deals with Abbott Laboratories Inc. and Bristol-Myers Squibb Co. (BMS). "These are both very large platform relationships," says Alan Roter, Iconix's vice president of informatics. Financial terms for the arrangement with Abbott were not disclosed, but Iconix stands to earn approximately US$24 million from its multi-year deal with BMS alone.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.